华创证券:给予康方生物-B(09926.HK)“买入”评级 目标价80.00港元

同花顺金融研究...
Jan 29, 2021

原标题:华创证券:给予康方生物-B(09926.HK)“买入”评级 目标价80.00港元 来源:同花顺金融研究中心华创证券1月29日发布公告。盈利预测、估值及投资评级。在当前国内抗体药物竞争激烈的产业环境下,康方生物实现了差异化布局,商业化潜力巨大。同时,AK104和派安普利单抗等产品均有望实现国际化。我们预计2020-2022年,公司有望实现主营收入0.37/4.90/14.68亿元,EPS-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10